SynthesisWorld journal of gastroenterology2013
Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.
Synthesis in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Guideline
- Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.Neurogastroenterology and motility · 2023Pooled it
- Thailand guideline 2020 for medical management of gastroesophageal reflux disease.Journal of gastroenterology and hepatology · 2022Guideline
- Vietnam Association of Gastroenterology (VNAGE) guideline on the management of gastroesophageal reflux disease.Frontiers in medicine · 2026Review
- Associations between excessive supragastric belching and esophageal reflux factors in patients with PPI-refractory GERD in Japan.Journal of gastroenterology · 2025Article
- Exploration of the potential therapeutic effects and targets of Coriandrum sativum on non-erosive esophagitis based on bioinformatics and molecular dynamics simulation.Scientific reports · 2025Article
- Short term safety of magnetic sphincter augmentation vs minimally invasive fundoplication: an ACS-NSQIP analysis.Surgical endoscopy · 2024Article
- Efficacy and safety of Jianpi Qinghua granules for non-erosive reflux disease with spleen deficiency and damp-heat syndrome: a multicenter, randomized, double-blind, placebo-controlled clinical trial.Frontiers in nutrition · 2024Article
- Article
- Progress on the Mechanism of Visceral Hypersensitivity in Nonerosive Reflux Disease.Gastroenterology research and practice · 2022Review
- Complex Gastroesophageal Reflux Disease.Gastro hep advances · 2022Review
- Article
- Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial.Journal of neurogastroenterology and motility · 2021Article
- Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Article
- Current Trends in the Management of Gastroesophageal Reflux Disease.Gut and liver · 2018Review
- Management of gastroesophageal reflux disease in adults: a pharmacist's perspective.Integrated pharmacy research & practice · 2018Review
- The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.Scientific reports · 2016Article
- Non-prescription treatment of NSAID induced GORD by Australian pharmacies: a national simulated patient study.International journal of clinical pharmacy · 2015Observational
- Effect of proton pump inhibitors on glycemic control in patients with diabetes.World journal of diabetes · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy, safety and influential factors of proton pump inhibitor (PPI) treatment for non-erosive reflux disease (NERD).
methodsPubMed, MEDLINE, EMBASE and the Cochrane Library were searched up to April 2013 to identify eligible randomized controlled trials (RCTs) that probed into the efficacy, safety and influential factors of PPI treatment for NERD. The rates of symptomatic relief and adverse events were measured as the outcomes. After RCT selection, assessment and data collection, the pooled RRs and 95%CI were calculated. This meta-analysis was performed using the Stata 12.0 software (Stata Corporation, College Station, Texas, United States). The level of evidence was estimated by the Grading of Recommendations Assessment, Development and Evaluation system.
resultsSeventeen RCTs including 6072 patients met the inclusion criteria. The results of the meta-analysis showed that PPI treatment was significantly superior to H2 receptor antagonists (H2RA) treatment (RR = 1.629, 95%CI: 1.422-1.867, P = 0.000) and placebo (RR = 1.903, 95%CI: 1.573-2.302, P = 0.000) for the symptomatic relief of NERD. However, there were no obvious differences between PPI and H2RA (RR = 0.928, 95%CI: 0.776-1.110, P = 0.414) or PPI and the placebo (RR = 1.000, 95%CI: 0.896-1.116, P = 0.997) regarding the rate of adverse events. The overall rate of symptomatic relief of PPI against NERD was 51.4% (95%CI: 0.433-0.595, P = 0.000), and relief was influenced by hiatal hernia (P = 0.030). The adverse rate of PPI against NERD was 21.0% (95%CI: 0.152-0.208, P = 0.000), and was affected by hiatal hernia (P = 0.081) and drinking (P = 0.053).
conclusionPPI overmatched H2RA on symptomatic relief rate but not on adverse rate for NERD. Its relief rate and adverse rate were influenced by hiatal hernia and drinking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.